Neurocrine Biosciences Launches Phase 3 Trial for Schizophrenia Drug NBI-1117568

MT Newswires Live

May 02, 2025

Nxera Pharma Co (TYO:4565) partner Neurocrine Biosciences has initiated a Phase 3 trial for NBI-1117568, an oral muscarinic M4 receptor agonist, for treating schizophrenia, according to a Thursday filing on the Tokyo Stock Exchange.

The trial follows positive Phase 2 results reported in August 2024, showing a significant reduction in symptoms.

The global, placebo-controlled trial will enroll around 280 patients with acute schizophrenia symptoms. The primary endpoint is the reduction of PANSS score, with secondary endpoints focusing on clinical severity.

No milestone payment is due at trial start, but a $15 million payment will be triggered when the first patient is dosed.

Price (JPY): $934.00, Change: $+18, Percent Change: +1.97%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2532596168"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2532596168\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2532596168?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-02 09:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2532596168","market":"fut","top_or_hot":-1,"title":"Neurocrine Biosciences Launches Phase 3 Trial for Schizophrenia Drug NBI-1117568","media":"MT Newswires Live","content":"<html><body><p> Nxera Pharma Co (TYO:4565) partner Neurocrine Biosciences has initiated a Phase 3 trial for NBI-1117568, an oral muscarinic M4 receptor agonist, for treating schizophrenia, according to a Thursday filing on the Tokyo Stock Exchange.</p><p>The trial follows positive Phase 2 results reported in August 2024, showing a significant reduction in symptoms.</p><p>The global, placebo-controlled trial will enroll around 280 patients with acute schizophrenia symptoms. The primary endpoint is the reduction of PANSS score, with secondary endpoints focusing on clinical severity.</p><p>No milestone payment is due at trial start, but a $15 million payment will be triggered when the first patient is dosed.</p><p>Price (JPY): $934.00, Change: $+18, Percent Change: +1.97%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurocrine Biosciences Launches Phase 3 Trial for Schizophrenia Drug NBI-1117568</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurocrine Biosciences Launches Phase 3 Trial for Schizophrenia Drug NBI-1117568\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-02 09:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Nxera Pharma Co (TYO:4565) partner Neurocrine Biosciences has initiated a Phase 3 trial for NBI-1117568, an oral muscarinic M4 receptor agonist, for treating schizophrenia, according to a Thursday filing on the Tokyo Stock Exchange.</p><p>The trial follows positive Phase 2 results reported in August 2024, showing a significant reduction in symptoms.</p><p>The global, placebo-controlled trial will enroll around 280 patients with acute schizophrenia symptoms. The primary endpoint is the reduction of PANSS score, with secondary endpoints focusing on clinical severity.</p><p>No milestone payment is due at trial start, but a $15 million payment will be triggered when the first patient is dosed.</p><p>Price (JPY): $934.00, Change: $+18, Percent Change: +1.97%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NBIX","symbol_name":"神经分泌生物科学","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2532596168","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2532596168","pubTimestamp":1746150527,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Nxera Pharma Co  partner Neurocrine Biosciences has initiated a Phase 3 trial for NBI-1117568, an oral muscarinic M4 receptor agonist, for treating schizophrenia, according to a Thursday filing on the Tokyo Stock Exchange.The trial follows positive Phase 2 results reported in August 2024, showing a significant reduction in symptoms.The global, placebo-controlled trial will enroll around 280 patients with acute schizophrenia symptoms. The primary endpoint is the reduction of PANSS score, with secondary endpoints focusing on clinical severity.No milestone payment is due at trial start, but a $15 million payment will be triggered when the first patient is dosed.Price : $934.00, Change: $+18, Percent Change: +1.97%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NBIX":"神经分泌生物科学","NBI":"纳斯达克生物技术指数","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","JPY":"Lazard Japanese Equity ETF","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4139":"生物科技","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC"},"translate_title":"Neurocrine Biosciences启动精神分裂症药物NBI-1117568的3期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NBI":1,"NBIX":1,"JPY":1},"content_text":"Nxera Pharma Co (TYO:4565) partner Neurocrine Biosciences has initiated a Phase 3 trial for NBI-1117568, an oral muscarinic M4 receptor agonist, for treating schizophrenia, according to a Thursday filing on the Tokyo Stock Exchange.The trial follows positive Phase 2 results reported in August 2024, showing a significant reduction in symptoms.The global, placebo-controlled trial will enroll around 280 patients with acute schizophrenia symptoms. The primary endpoint is the reduction of PANSS score, with secondary endpoints focusing on clinical severity.No milestone payment is due at trial start, but a $15 million payment will be triggered when the first patient is dosed.Price (JPY): $934.00, Change: $+18, Percent Change: +1.97%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}